Search 

Articulate Labs builds wearable medical devices amplify muscle growth throughout everyday activity to help others conquer functional limitations and to restore physical capability

Astrocyte Pharmaceuticals is a preclinical CNS drug development company advancing breakthrough therapeutic agents for treating brain injury patients. Astrocyte is developing the proprietary small molecule pharmaceutical agent AST-004 for acute administration to patients who have suffered a stroke, TBI, or concussion. This product would be administered by intravenous injection by emergency responders or a medical professional within 24 hours of injury to limit neuronal damage and cell death. Our approach at Astrocyte Pharmaceuticals differs significantly from historical neuroprotective attempts as we focus on a non-neuronal cell type, the astrocyte, which is the most common cell type in the human brain and has only recently received broader attention as an important cellular target for therapeutic research. The company recently demonstrated AST-004's significant efficacy in an NHP stroke study that mirrors the planned Phase 2 clinical study, and large safety margins in GLP toxicology studies. The company completed its Series A financing in Q4 2020.